<author lang="en" gender="female" age_group="20s">	<conversations count="24">		<conversation id="9d610b7ea6ec0af85bf9bee66775c4a4">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2011%2F12%2Fadverse-effects-of-ruxolitinib.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2011/12/adverse-effects-of-ruxolitinib.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Adverse effects of ruxolitinib treatment discontinuation in MPNs		</conversation>		<conversation id="2417a6f0c13a223f8069e4bd32aaeaf6">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2011%2F12%2Froles-of-jakstat-pathways-in-traumatic.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2011/12/roles-of-jakstat-pathways-in-traumatic.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Roles of JAK/STAT pathways in traumatic brain injury		</conversation>		<conversation id="8604429a8b9569e1f3a416998b2a9d2b">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2011%2F12%2Fcombinatorial-peptide-ps-5-more.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2011/12/combinatorial-peptide-ps-5-more.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;The combinatorial peptide PS-5, the more effective inhibition on JAK/STAT pathway		</conversation>		<conversation id="f13c3d09f9f1074dd68ac5fdac84860b">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2011%2F12%2Fepigenetic-alterations-in.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2011/12/epigenetic-alterations-in.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Epigenetic alterations in myeloproliferative neoplasm (MPN)		</conversation>		<conversation id="4185b5a1de6f258b29007ba43136012d">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2011%2F12%2Fsgi-1776-potential-therapy-against-aml.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2011/12/sgi-1776-potential-therapy-against-aml.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;SGI-1776, the potential therapy against AML		</conversation>		<conversation id="1e3bad7246c6029dfcd751283299ca53">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2011%2F12%2Fm-110-novel-pim-inhibitor.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2011/12/m-110-novel-pim-inhibitor.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;M-110, the novel Pim inhibitor		</conversation>		<conversation id="53f8a2a4c622ee7cfec5b4d363d7ccde">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2012%2F01%2Fcombination-treatment-of-pim-inhibitor.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2012/01/combination-treatment-of-pim-inhibitor.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Combination treatment of Pim inhibitor SMI-4a and ABT-737 against prostate cancer		</conversation>		<conversation id="2d3129e6e60ca1124a25509caa593e90">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2012%2F01%2Ffungal-treatment-for-dengue.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2012/01/fungal-treatment-for-dengue.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Fungal treatment for dengue transmission		</conversation>		<conversation id="b6aaad8b8feb40a799169b50a4081caf">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2012%2F01%2Fnutrition-regulated-lipolysis-in-fish.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2012/01/nutrition-regulated-lipolysis-in-fish.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Nutrition-regulated lipolysis in fish and the associated signaling pathways		</conversation>		<conversation id="d516a30727611dfab442e55737d32845">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2011%2F12%2Fifn-signaling-pathway-and-hepatitis-e.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2011/12/ifn-signaling-pathway-and-hepatitis-e.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;IFN-? signaling pathway and hepatitis E		</conversation>		<conversation id="516c426b47246970531caa10385f6b30">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2011%2F12%2Fthymoquinone-potential-agent-in.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2011/12/thymoquinone-potential-agent-in.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Thymoquinone, a potential agent in the treatment of MM		</conversation>		<conversation id="40f1e30a461db85120ea123dd479bd84">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2011%2F12%2Fnew-insight-for-treatment-of-diabetic.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2011/12/new-insight-for-treatment-of-diabetic.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;New insight for the treatment of diabetic complications of the CNS.		</conversation>		<conversation id="3402b559f395b6fedcac616bc742beb1">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2011%2F12%2Fexploration-of-targets-for-crohns.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2011/12/exploration-of-targets-for-crohns.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Exploration of targets for Crohnâ€™s disease		</conversation>		<conversation id="5d8e332d240668f35f8f565cd9f46933">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2012%2F01%2Froles-of-socs-protein-in-fish.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2012/01/roles-of-socs-protein-in-fish.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Roles of SOCS protein in fish		</conversation>		<conversation id="ec3edb9fc3e4a005f326a9eded8a3949">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2012%2F01%2Ffollicular-lymphomas-and-immunotherapy.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2012/01/follicular-lymphomas-and-immunotherapy.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Follicular lymphomas and immunotherapy with Rituximab		</conversation>		<conversation id="a70686cd4523e9c99a5f2d50317227d6">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2012%2F01%2Factivators-of-jakstat-pathways-in.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2012/01/activators-of-jakstat-pathways-in.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Activators of JAK/STAT pathways in treatment of virus diseases		</conversation>		<conversation id="b08dbbf7fe3dceb3f840fc1138b53510">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2012%2F01%2Fstat3-target-for-nsclc-therapy.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2012/01/stat3-target-for-nsclc-therapy.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;STAT3, the target for NSCLC therapy		</conversation>		<conversation id="39e5d63c270e3d0b319850b3508887e3">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2012%2F01%2Fsince-i-have-talked-about-study-of.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2012/01/since-i-have-talked-about-study-of.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Combination therapy of a pan-JAK inhibitor and a BCR-ABL inhibitor in CML		</conversation>		<conversation id="7f3dc130b4672c53ee8999b28a100106">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2012%2F01%2Fassociation-of-pdgfr-signaling-pathways.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2012/01/association-of-pdgfr-signaling-pathways.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Association of PDGFR signaling pathways and other pathways MSCs		</conversation>		<conversation id="8dd6e86718e04bb4218b4d5d5c8d2d14">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2012%2F01%2Fag490-and-hepcidin-mediated-diseases.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2012/01/ag490-and-hepcidin-mediated-diseases.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;AG490 and hepcidin-mediated diseases		</conversation>		<conversation id="7c1a49d0676066cdaceb1a69e61e5bc">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2012%2F01%2Froles-of-il-4-and-jakstat-pathway-in.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2012/01/roles-of-il-4-and-jakstat-pathway-in.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Roles of IL-4 and JAK/STAT pathway in atopic dermatitis		</conversation>		<conversation id="7adb5c5b17563d3ba9526e4b80dc7b66">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2012%2F01%2Fmeasles-virus-infection-and-jakstat.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2012/01/measles-virus-infection-and-jakstat.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Measles virus infection and JAK/STAT pathways-kinase inhibitors INCB018424 CP-690550		</conversation>		<conversation id="90f653245c2f4811fcf0c12a902e9459">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2012%2F01%2Fchronic-hypoxia-in-prostate-cancer.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2012/01/chronic-hypoxia-in-prostate-cancer.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Chronic hypoxia in prostate cancer-kinase inhibitor, LY294002, pi3k inhibitor		</conversation>		<conversation id="eace1cddb654d6fa609b94623c1cdd6">			&lt;a href="http://en.pan.netcom/go/out/url=http%3A%2F%2Fwww.jakstatpathway.com%2F2012%2F01%2Feffects-of-melatonin-on-microglia-and.html"target="_blank" rel="nofollow"&gt;;http://www.jakstatpathway.com/2012/01/effects-of-melatonin-on-microglia-and.html&lt;/a&gt;; 
&lt;br /&gt;;&lt;br /&gt;;Effects of melatonin on microglia and the possible mechanism-kinase inhibitor, LY294002, pi3k inhibitor		</conversation>	</conversations></author>